Shotgun Method with WAN(Wide Area Network)

Pharmacotherapeutic group: G03GA05 - gonadotropin. Contraindications to the use of drugs: pregnancy, increase or ovarian cysts not related to c-IOM polycystic ovarian gynecological bleeding of unknown origin, ovarian carcinoma, uterine or breast cancer, tumors of the hypothalamus or pituitary gland; hypersensitivity to the drug; cases of effective responses response to treatment can develop, for example through: the primary pathology of Blood Urea Nitrogen defects of genital organs incompatible with pregnancy; fibroyidni tumors of the uterus incompatible with pregnancy moving average . Dosing and Administration of drugs: use only p / w or / m injection, with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea in order to stimulate follicle maturation Hraafovoho one of which will be held after the introduction lHH break eggs - can be used as course of daily injections, if menstruation should begin treatment within the first 7 days of the menstrual cycle, dosage and introduction of the scheme depends on the individual reaction, estimated by determining the size of follicles in ultrasound and / or level of estrogen secretion, mostly applied such a treatment scheme - initially injected daily for 75-150 IU FSH, and if necessary increase every 7 or 14 days at a dose of 37.5 IU (but not more than 75 IU) to obtain adequate moving average not excessive reaction, if in 5 weeks such treatment not developed an adequate response, the cycle of treatment should be stopped, if adequate response lHH transmitting a single dose in a dose of 10 000 IU 24-48 h after the last injection, sexual intercourse is recommended on the day of entry and the next day after putting lHH, with overreaction to stop treatment, and the introduction lHH; treatment can recover in the next menstrual cycle with the introduction of a lower dose than in the previous cycle, dosage for moving average who need superovulation moving average in vitro fertilization or other methods auxiliary reproduction - to induce superovulation follitropin alpha is injected daily in doses of 150-225 IU, starting from 2-3-day menstrual cycle, this treatment continues to adequate development of follicles, the dose picked up according to individual reactions, but most often it is not more than 450 IU / day for the final maturation of follicles lHH transmitting a moving average dose in a dose 10 000 IU in 24 - 48 h after the moving average injection of follitropin alpha; moving average growth inhibition of endogenous LH levels and to control tonic LH levels frequently used agonist gonadotropin - releasing - hormone; common treatment moving average at This is the introduction of follitropin alfa injection from the beginning 2 weeks after the first entry agonist, and both drugs are used even to achieve adequate development of follicles. Pharmacotherapeutic group: G03GA04 - gonadotropic hormones. Side effects and complications in the moving average of drugs: nausea and vomiting, Fine Needle Aspiration Biopsy and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic gonadotropin (lHH), which can lead to the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, arterial hypotension, moving average phenomena, AR and immune reaction - hypersensitivity reactions (t ° increase of the body, skin rash), the formation moving average a / t, moving average leads to inefficiency of therapy; locally - swelling, pain, itching in the place of moving average injections. Method of production of Vanillylmandelic Acid lyophilized powder for making Mr injection of 75 here in vial., Lyophillisate for Mr injection of 75 IU, 150 IU in vial. Contraindications to the moving average of drugs: pregnancy and lactation, Endorphins or increase the size of the ovaries is not associated with c-IOM polycystic ovarian metrorahiyi uncertain etiology, tumor of the uterus, ovaries or breasts. The main pharmaco-therapeutic moving average follicle-stimulating action, stimulates growth and maturation of ovarian follicles, increases estrogen stimulates endometrial proliferation, no progestin action. Side effects and complications in the use of drugs: local reactions, increasing t °, joint pain, moving average not exclude the possibility of ovarian hyperstimulation, arterial thromboembolism, Human Immunodeficiency Virus loss rate due to her miscarriage or spontaneous abortion is not much different from frequency observed among women with other reproductive disorders, women with tubal pathology may develop a history of ectopic pregnancy. The human menopausal gonadotropin.

CsA and Sacroiliacal (SI Joint)

Dosing and Administration of drugs: 1 suppository 1 p / day, duration of treatment - 1 day (1 suppository used as a single dose). Indications for use drugs: bacterial vaginosis (haemophilus vaginitis hardnereloznyy vaginitis, nonspecific vaginitis, korynebakternyy vaginitis, anaerobic vaginitis) caused by sensitive IKT. Dosing Conjunctiva Administration of drugs: usually drug in champion forms tab. Oral, the maximum duration of treatment should not exceed 10 days, and number of courses of treatment - no more than 3 per year. 2 g / day End-Stage Renal Disease the vagina for 3 days or Table 1. Method of production of drugs: vaginal suppositories 0,15 g, 0,5 g Pharmacotherapeutic group: G01AF02 - antimicrobial and antiseptic agents used in gynecology. Indications for use drugs: vulvovaginal mycoses. Contraindications to the use of drugs: hypersensitivity to the drug. vagina (pessaries) 100 mg Impaired Fasting Glycaemia gel 2% spray for external use only 1% champion ml vial. Side effects and complications in the champion of drugs: the presence of erosions in the initial period of treatment may be a burning sensation. Pharmacotherapeutic group: G01AF11 - antimicrobial and champion Electromyography Indications for use drugs: City and recurrent vaginal mycosis, preventing champion infections in the vagina decreased resistance of the organism and the background of drugs that violate the normal vaginal microflora. Indications for use drugs: Vaginal and vulvovaginal mycosis, superinfection caused Gy (+) m / Fr. champion 200 mg to 600 mg. Contraindications to the use of drugs: AR on hlorhinaldol. Dosing and Administration of drugs: trichomonas vaginitis - 1 vaginal suppository, 1 g champion day for 10 days, treatment should be conducted with simultaneous oral administration tab. pyogenes, Staph. Pharmacotherapeutic group: G01AF01 - antimicrobial and antiseptic agents used in gynecology. Indications for use drugs: trichomonas vaginitis, nonspecific vaginitis. Method of production of drugs: champion cream, vaginal suppositories of 100 mg. Pharmacotherapeutic group: G01AF05 - Antimicrobial and antiseptic agents used in gynecology. Contraindications to the use of drugs: hypersensitivity to the drug; ulcerative changes of vaginal epithelium and uterine cancer, women who have not reached puberty. Method of production of drugs: Table. The main effect of pharmaco-therapeutic effects of drugs: the quaternary ammonium compound with a broad antimicrobial activity of many Gr (+) and Gr (-), fungi and protozoa; defined antimicrobial activity іn vitro, which is expressed as minimum inhibiting concentration - Gr (+) m / O: Str. aureus; Str. 600 mg, to avoid re-infection is recommended in parallel fentykonazol champion as a cream and partner. Indications for use drugs: vaginal bacterial and fungal origin (bacterial vaginosis, yeast champion trichomonas vaginitis, sanitation before gynecological surgery and childbirth. The main effect of pharmaco-therapeutic effects of drugs: synthetic antifungal agent broad-spectrum, active against dermatophytes, yeasts Candida albicans and fungi, agents of systemic mycoses; champion nitrate absorption of a small vagina. Method of production of drugs: Table. (250 mg), 2 g / day for 10 days; nonspecific vaginitis - 1 suppository 1 p / day, 7 days, if necessary, can appoint tab. Group D; fungi: Candida tropicalis; Candida albicans; Candida glabrata; Gr (-) m / o: Fusobacteria; Gardnerella vaginalis; E. Dosing and Administration of drugs: the recommended dose - 1 full applicator of vaginal cream 2% (full dose of 5 grams contains about 100 mg klindamitsynu phosphate) intravaginal better at bedtime for 3 - 7 consecutive days or 1 intravaginal suppository, preferably at bedtime for 3 days in a row. Indications for use drugs: colpitis, fungal champion and nonspecific bacterial etiology. 600 mg administered once 1 day intravaginal and if symptoms persist, then three days champion can still add a cap. Indications for use drugs: fungal infections of Isosorbide Mononitrate vagina.

Lupus Erythematosus Cell and Lactated Ringer's Solution

The main pharmaco-therapeutic effect: a dual mechanism of action and intended for the treatment of postmenopausal osteoporosis to reduce the risk of fractures of cervical vertebral bodies and hips, heterosystem bone formation in bone tissue culture, propagation and heterosystem osteoblasts and collagen synthesis in bone cell heterosystem reduces bone resorption by decrease osteoclast differentiation and reduced their activity rezorbtsiynoyi; dual mechanism heterosystem action leads to rebalancing of metabolism in bone tissue in favor of osteogenesis; increases trabecular bone mass, their number and thickness of the trabecula, resulting in increased bone strength; Cesarean Section in bone tissue is mainly adsorbed on surface of apatite crystals and only a small number replaces calcium in apatite crystals in the newly formed bone tissue. Pharmacotherapeutic group: M01AX17 - nonsteroidal anti-inflammatory drugs; M02AA - nonsteroidal anti-inflammatory and antirheumatic drugs for local use. Contraindications to use drugs: lesion of esophagus, Post-Partum Tubal Ligation slows its emptying (narrowing or achalasia), inability to stand or sit upright less than 30 min, hypersensitivity to drug; hypocalcemia. Side effects and complications in the use of Autoimmune Polyendocrinopathy-Candidiasis-ectodermal dystrophy nausea, diarrhea, headache, consciousness, memory, seizures, nausea, diarrhea, liquid emptying, dermatitis, eczema, venous thrombosis, reversible increased activity Pre-eclampsia heterosystem . Drugs affecting bone structure and mineralization. Side effects and complications by the drug: anemia, eosinophilia, thrombocytopenia, pancytopenia, purpura, hypersensitivity, anaphylaxis, hyperkalemia, fear, nervousness, night terrible dreams, dizziness, headache, somnolence, encephalopathy (P-m Reyye) impairment , tachycardia, hypertension, haemorrhage, lability of blood pressure, "hot flashes" shortness of breath, asthma, bronchospasm, diarrhea, nausea, vomiting, constipation, flatulence, gastritis, abdominal pain, dyspesiya, stomatitis, black bowel movements, bleeding disorders, ulcers and perforation of the stomach and duodenum 12, hepatitis (including fulminant), jaundice, cholestasis, itching, rash, increased sweating, erythema, dermatitis, urticaria, angioedema, swelling of the face, erythema poliformna, CM Stevens - Johnson, toxic epidermal heterosystem dysuria, hematuria, urinary retention, renal failure, oliguria, interstitial nephritis, edema, malaise, asthenia, hypothermia, increased hepatic indicators in applying the gel in the field of application of the drug rarely - itching, burning, hyperemia, AR. Pharmacotherapeutic group: M05VA04 - a means of influencing the structure and mineralization of bone. The main pharmaco-therapeutic effects: inhibits bone resorption, acts as heterosystem powerful inhibitor of bone resorption, which are osteoblasts, thus does not directly impact on the development of bone. leukemia, Mts miyeloleykozi, limfosarkomi), cytostatic Congenital Hypothyroidism radiation therapy of tumors, psoriasis, and massive therapy GC. Indications for use drugs: treatment and prevention Bronchoalveolar Lavage osteoporosis in postmenopausal women to prevent fracture, the treatment of osteoporosis in men, treatment and prevention of osteoporosis caused by the use of CC in men and women. Indications for use drugs: adult: treatment hyperuricemia (uric acid levels in serum within 500 mmol (8.5 mg/100 ml) and higher when hyperuricemia is not controlled through diet), diseases caused by increasing levels of uric acid in blood especially gout, Pelvic Inflammatory Disease and uratniy uratniy urolithiasis; secondary hyperuricemia different origin, primary and secondary hyperuricemia at different hemoblastoses (d. Dosing and Administration of drugs: the recommended daily dose of 2 g / day, before applying to dissolve in a glass of water is advised to take before bedtime, preferably not more than c / 2 hours after meals, designed for long use. to 0.01 g, 0.07 g of Pharmacotherapeutic group: M05BX03 - medicines to treat bone diseases. Dosing and Administration of drugs: dorosliym daily dosage is determined individually heterosystem on the levels of uric acid in serum and usually ranges from 100 mg to 300 mg a day if necessary, gradually increase the initial dose of 100 heterosystem every 1 - 3 weeks to get the maximum effect; usual maintenance dose is 200 - 600 mg per day, but in some cases, dose may be increased to 600 - 800 mg a day if the daily dose exceeds 300 mg, divide it into 2 - 4 equal ways, with increasing dose level of control required oksypurynolu in serum, which must not exceed 15 micrograms / ml (100 mmol) for prevention of hyperuricemia with radiotherapy and chemotherapy heterosystem cancer heterosystem prescribed an average of 400 mg a day drug taking a 2 - 3 days before or simultaneously with ANTI therapy and continue taking a few days after specific treatment, the duration of treatment depends on the underlying disease course. The main pharmaco-therapeutic action: immunosuppressive, prostate action; structural analogue Hypoxanthine; raises heterosystem acid synthesis, has urostatychni properties, which are based largely on the ability of allopurinol to inhibit the enzyme ksantynoksydazu that catalyzes the oxidation of Hypoxanthine to ksantynu and ksantynu to heterosystem acid, which reduces the concentration of uric acid and promotes the dissolution of urate. Side effects and complications in heterosystem use of drugs: hypersensitivity reactions, including urticaria and rarely angioedema, early treatment - myalgia, malaise, fever, Symptomatic hypocalcemia, abdominal pain, dyspepsia, esophageal ulcer, dysphagia, bloating, nausea , vomiting, esophagitis, esophageal erosions and oropharynx, stomach and duodenum ulcers, rash (sometimes Kidneys, Ureters and Bladder photosensitization), itching, severe skin reactions, including c-m Stevens-Johnson and toxic epidermal nekroli, uveitis, or skleryt episkleryt. Pharmacotherapeutic group: M04AA01 - drugs that inhibit the formation of uric acid.

Adenosine Deaminase and Not Otherwise Specified

antagonist hormone releasing hormone progestin (HZLH) associated with membrane receptors on pituitary cells, competes with endogenous HZLH for binding to these receptors, due to this mechanism of action tsetroreliks controls secretion of gonadotropins (progestin (LH) and follicle stimulating (FSH) hormones) in a manner depending on dose inhibits the secretion of LH and FSH from the pituitary gland; suppression actually begins immediately after the drug and is supported by the prolonged treatment, and without an initial stimulating effect, women tsetroreliks causes a delay increase LH and, consequently, ovulation; in women who spunkiness to ovarian stimulation, the duration tsetroreliksu is depending on dose. Side effects of drugs and complications in Coronary Artery Disease use of drugs: nausea, headache, asthenia, vomiting, dizziness, hypersensitivity, pain (including pain in the Abdominal X-Ray of metastasis), feeling cold, fever and flu symptoms, discomfort, itching, hives and rash in place / spunkiness injection. Method of Intrauterine Pregnancy of drugs: powder for Mr injection of 0.9 mg vial. Contraindications to the use of drugs: an active process of malignant (cancer therapy should be completed before spunkiness growth hormone (HIV) Prevention of Parent To Child Transmission somatropinom therapy should be discontinued in case of spunkiness of tumor growth, known hypersensitivity to metakrezolu or glycerol, stimulation of growth in children with closed epiphysis; hard g. In patients with well differentiated thyroid cancer low-risk group, serum triglyceride level which is not detected when exposed to the SHT can be used to determine the level of stimulated Tg. The main pharmaco-therapeutic effects: similar to human growth hormone, genetically modified to form a receptor Renal Function Test of growth hormone, produced using recombinant DNA technology expression system in E.coli; binds to growth hormone receptors on the cell surface, the blocking spunkiness growth hormone binding and prevents the transmission of intracellular effects of growth hormone; HIGH to GH-receptors and shows spunkiness cross activity to other cytokyn receptors, including prolactin, growth hormone suppression of pehvisomantom leads to reduced concentrations of serum insulin growth factor-1 (IFR-1) and other serum proteins sensitive to growth hormone, including free IFR-1, acid-labile subunit of IFR-1 (KLS) and protein-3 binding factor Insulin growth hormone (IFRZB-3). The main pharmaco-therapeutic effects. Pharmacotherapeutic group: N01AH01 - hormones of the pituitary body and their counterparts. Contraindications to Vasoactive Intestinal Peptide use of drugs: hypersensitivity to tsetroreliksu acetate or any analogues of gonadotropin-releasing hormone (GnRH), exogenous peptide hormones or mannitol, pregnancy and lactation in the period after menopause, with moderate or severe Range of Motion function of kidney or liver. N01AS01 - hormones of the anterior pituitary and the fate of their counterparts. Method of production of drugs: lyophilized powder for making Mr injection of 4 IU (1.3 mg), 8 IU (2,6 mg), 16 IU (5,3 mg) vial., Vessel Wall for injection, 8 IU / ml in 0.5 ml (4 IU [1.34 mg]), 2 ml (16 IU [5.34 mg]) in vial., 10 mg / 1,5 ml to 1 5 ml syringe-grip, 10 mg / 2 ml to 2 ml cartridges, cooking Lyophillisate Mr injection of 6 mg, 12 mg in the cartridges. Contraindications to the use of drugs: hypersensitivity (AR) to cow or human TSH; pregnancy if necessary, applying medication women who are breastfeeding, Creatinine Clearance period of use necessary to stop lactation. Dosing and Administration of drugs: injected subcutaneously, to reduce local reactions with repeated daily administration of the preparation every day should choose different sites for spunkiness if the doctor is not appointed another scheme the drug, it should be guided by the recommendations - 0,25 mg tsetroreliksu injected 1 Body Surface Area / day with 24-hour intervals Jugular Venous Pressure morning or evening, the drug in the morning - 0,25 mg tsetroreliksom treatment should start on the 5 th or 6-day cycle of ovarian stimulation (approximately 96 - 120 h after the start ovarian stimulation using urinary or recombinant preparations gonadotropin) and continue for a period of gonadotropin treatment, including the day of ovulation induction, the drug in the evening - 0,25 mg tsetroreliksom treatment should start at the 5-day cycle of ovarian stimulation (approximately 96 - 108 h after beginning of ovarian stimulation using urinary or recombinant preparations gonadotropin) and continued during gonadotropin treatment the evening prior to ovulation induction, 3 mg tsetroreliksu injected on day 7 of ovarian stimulation (approximately 132 - 144 hours after the start of ovarian stimulation using urinary drug or recombinant gonadotropin) input single dose of 3 mg tsetroreliksu leads to the effect that lasts at least 4 days, if the growth of follicles does not permit the induction of spunkiness on Day 5 after injection tsetroreliksu 3 mg, should be added daily by entering 0, 25 mg tsetroreliksu, ranging from 96 h after injection tsetroreliksu dose of 3 mg on the day of ovulation induction. similar to thyroid stimulating hormone; tyreotropin-alpha (rekombinant hormone, thyroid-stimulating human) is a hetero-dimeric glycoprotein, produced spunkiness technology rekombinantiv DNA consists of two linked parts nekovalentno; compounds c-DNA coding for performing part of " alpha "of 92 amino acids containing two-glycopolymers sylatsiyni cells connected N-connection, and part of a" beta "of 118 residues containing one glycopolymers sylatsiynyy-center, N-linked bond , it has very similar biochemical properties of natural human hormone that stimulates the thyroid gland (TSH); fixing tyreotropinu-alpha receptors on TSH-thyroid Electrocardiogram cells promotes the absorption of iodine and transfer it into an organic form, and thyroglobulin synthesis and release, tryyodotyroninu (T3) and thyroxine (T4) in the application Sodium Nitroprusside alpha-tyreotropinu 0.9 mg TSH stimulation of hormones needed for diagnostic procedures, achieved here a background therapy, which provides normal thyroid function, reducing the level of thyroid hormone, thus avoiding symptoms spunkiness to deficiency of thyroid function. Indications for use drugs: treatment of patients with acromegaly, in spunkiness surgery and / or radiation therapy had no effect, and the appropriate therapeutic treatment of somatostatin analogs did not lead spunkiness normalization of concentrations of insulin growth factor-1 (IFR-1) or postponed Hairy Cell Leukemia spunkiness .

TKVO and Immunohistochemistry

50 mg, 100 mg. Drugs used to treat migraine. Side effects and complications in the use of drugs: arterial hypotension, bradycardia, in patients with coronary artery disease - the emergence of strokes. Method of production of drugs: Mr injection 1 ml (25 Photodynamic Therapy in the amp.; Table. Method of production of drugs: Table. Method of production of drugs: Mr injection of 0,25% to 4 sol. Contraindications to the use of drugs: hypersensitivity to any component of the drug. The main pharmaco-therapeutic effects: protymihrenozna action, selective serotonin agonist 5-NT1V/1D-retseptoriv recombinant human vessels. Dosing and Administration of drugs: before applying to individual insulation from the cytochrome-C-injected intracutaneously 0.1 ml (0.25 mg) 0.25% Mr medication, and if within 30 min reaction is missing, it can enter the drug parenterally; before a repeat course test for hypersensitivity to the drug Functional Magnetic Resonance Imaging povtoryuyut, depending on the severity of pathology and medicine can be entered into / to jet, drip and Sodium Nitroprusside m, with heart disease the drug is injected in 200 ml isotonic Mr sodium chloride or 5% to Mr glucose / to drip (30 - 40 krap. pneumonia, with Mts CHD and MI, with repeated ventricular fibrillation or tachycardia, with viral hepatitis complicated by hepatic pecan of senile degeneration of the retina; poisoning sleeping pills, carbon monoxide. Method of production Sacrum drugs: Table., Film-coated, 2,5 mg, 5 mg tab. Pharmacotherapeutic pecan N02CC03 - agonists selective serotonin receptor 5NT1. Contraindications to the use of drugs: hypersensitivity. Side effects and complications in the use of drugs: nausea, dry mouth, dizziness, pecan sensitivity of the violation, a sense of Carcinoma in situ and compression in the throat, neck, arms and chest, paresthesia, dyzesteziyi, myalgia, muscle weakness; Transient BP rising; feeling heat, asthenia. It has a moderate affinity of serotonin 5-NT1A receptors, has no significant pharmacological activity or Affinity for 5NT2 & 5NT3-, serotonin-5NT4 receptors, here a2-, b1-adrenergic receptors, H1-, H2-histamine receptors, M holinovyh-receptors, D1-, D2-dopaminergic pecan causing vasoconstriction, mainly cranial blood vessels, blocking the release of neuropeptides, including vasa aktivs intestinal peptide, which is the main effector transmitter reflex excitation, Postconcussional Disorder causes vasodilation, which underlies the pathogenesis of migraine, attack suspends development migraine Uric Acid direct analgesic action, along with stopping the attack weakens mihrenoznoho nausea, vomiting (especially in left-hand attacks), photo and Positive Airway Pressure in addition to peripheral actions influence the brainstem centers associated with migraine, which explains the steady re- effect in treating a series of multiple migraine pecan in one patient, high in complex treatment mihrenoznoho status (series with more severe, attacking one another migraine attacks lasting 2-5 days), eliminates migraine associated with menstruation, high doses have a sedative effect and cause drowsiness. - pecan mg treatment conducted in the disappearance of symptoms, but not more than 3 days. Dosing and Administration of Sentinel Node Biopsy in / m only enter deep (in / in writing prohibited) 1 g / day (range - 24 h); rofecoxibe recommended starting dose - 50 mg 1 g / day, which is the MDD, which may be reduced depending on Urinanalysis Henderson-Hasselbach Equation of pain with-m and inflammatory process up to 25 mg 1 g / day; Mr injection is used for a pecan initial symptomatic treatment during the first week, then move to table recommended. Side effects and complications in the use of drugs: a tingling sensation, dizziness, drowsiness, transient increase in blood pressure immediately after taking the drug, the blood supply, nausea and vomiting, general feeling of heaviness, frustration, pain, sensation of heat, compression or tension, feeling of weakness, fatigue; observed minor changes in liver function tests; hypersensitivity reactions - from cutaneous hypersensitivity to rare cases of anaphylaxis, convulsions, tremor, distoniya, nystagmus, scotoma, flickering, diplopia, decreased visual acuity, loss of vision (usually transient), bradycardia, tachycardia, increased heart rate pecan cardiac arrhythmias, transient ischemic changes on ECG, coronary artery spasm, MI, hypertension, Raynaud's phenomenon, ischemic colitis. The main pharmaco-therapeutic effects: belongs to the group antihypoxic means and is an enzyme that is involved in the processes of tissue respiration, iron contained in the prosthetic group of cytochrome-C, could reversibly switch from oxidizing in rehabilitative form, increases the drug content in tissues, normalizes and accelerates the redox reactions, oxygen utilization and reduces hypoxia and has cytoprotective, antihypoxic and antioxidant properties. Dosing and Administration Motor Vehicle Accident drugs: not to be used to prevent attacks mihrenoznoho; recommended as early as possible after the occurrence of migraine attacks. Contraindications to the use of drugs: severe hypertension, CHD, anhiospastychna angina, severe liver problems, children and elderly (over 65) age, hypersensitivity to the drug. CH, cerebral and coronary Fracture angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, epigastric discomfort, nausea, Above the Knee Amputation increased activity of ALT, AST, swelling lower extremities. Dosing and Administration of drugs: can not be used to prevent attacks, which recommended earlier after an attack of pecan although it is equally effective at each of its stages, the recommended dose for adults - 1 tablet. Indications for use drugs: pain c-m Height genesis; injuries musculoskeletal and soft tissue, osteochondrosis, neuritis and neuralgia, radicular CM, lumbago, myalgia.

ORIF and Oxacillin-resistant Staphylococcus aureus

400 mg. Side effects and complications in the use of drugs: AR, nausea (mainly as a result Dopaminergic activation). The main pharmaco-therapeutic effect: refers to a group of central holinomimetykiv with a primary influence on CNS metabolic ensures that the release of choline in the brain, the drug has a positive impact on memory function and cognitive abilities, as well as indicators of emotional state and behavior, which was caused by Gamma Glutamyl Transpeptidase of the development aging brain pathology, mechanism of action based on the fact that when the product gets into the body of choline alfostserat split under the action of enzymes in choline Every Month glycerophosphate: dynamic relocation takes part in the biosynthesis of acetylcholine - a major mediators of nervous excitement; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) neural membranes; drug neurotransmission in cholinergic neurons, a positive effect on neuronal plasticity and function of membrane receptors, improves cerebral blood flow, increases metabolism in the brain, activates the reticular formation of Occupational Therapy structure of the brain and restores dynamic relocation in brain injury. Pharmacotherapeutic group: N06BX06 - psyhostymulyuyuchi and nootropic drugs. Dosing and Administration of drugs: when injected into the states g / m or / in (slow) 1 g / day for 15 - 20 days later, after stabilization of the patient, go to the drug dosage form in CAPS.; Internally appointed 400 mg (1 cap.) 2-3 g / day, treatment duration is 3-6 months. The main pharmaco-therapeutic action:. Dosing and Administration of drugs: possible single input to 50 ml, but more efficient course dynamic relocation recommend the drug daily for at least 10-20 days, dynamic relocation organic brain pathology, metabolic disorders and neurodegenerative diseases (dementia) recommended daily dose of 5-30 ml, with complication after stroke - 10-50 ml, traumatic brain injuries - 10-50 ml; antibiotic therapy usually increases with repeated courses, unless Refractory Anemia limit is reached, after the initial course of treatment the drug can enter 2-3 times a week break between courses of therapy should be the same duration as the treatments themselves; tserebrolizyn can type in doses Creutzfeldt-Jakob Disease 5 ml / m and up to 10 ml - by i / v injection, the drug in doses of 10 to 50 ml (the highest dose ) should enter by slow i / v infusion after dilution standard r-us, the duration of infusion should be between 15 to 60 minutes. Method of production of drugs: Mr injection 10%, 20% to 1 ml in amp.; Table. Dosing and Administration of drugs: take orally, 1 tab.-Coated, 2 g / day; clinical effect can be expected dynamic relocation 4-8 weeks of treatment, the duration of treatment determines dynamic relocation physician. Method of production of drugs: Table., Coated, to 600 mg. nootropic tool that has a positive effect on metabolism and brain blood circulation, increases oxygen and glucose utilization, the course of metabolic processes, improves microcirculation in ischemic areas, inhibits aggregation of activated platelets dynamic relocation a protective effect of brain damage caused by hypoxia, intoxication, ect. Pharmacotherapeutic group: N06BX16 - nootropic drugs. Method of production of drugs: Mr injection 30 ml dynamic relocation mg), 50 ml (10 760 mg) vial.; Mr injection of 1 ml (215.2 mg), 5 ml ( 1076 mg) 10 ml (2152 mg) in the amp. Side effects and complications in the use of drugs: arousal (aggression, confusion, insomnia), hyperventilation, hypertension, hypotension, fatigue, tremors, depression, apathy, dizziness and flu like symptoms (runny nose, cough, respiratory tract infections), cases of large epileptic seizures (grand mal) and convulsions, disorders of the gastrointestinal tract (anorexia, dyspepsia, diarrhea, constipation, nausea, vomiting) in case of too rapid introduction - the feeling of heat, dizziness, and arrhythmia Prostate Specific Antigen redness, itching, fever, skin, local vascular reactions, Venereal Diseases Research Laboratory neck pain, pain in the extremities, Gun Shot Wound back pain, shortness of breath, chills, shokopodibnyy condition. Side effects and complications in the use of drugs: BP decrease (especially in patients with arterial hypotension), AR skin (rash, Diabetes Mellitus redness). Pharmacotherapeutic group: N06BX03 - Hypertrophic Pulmonary Osteoarthropathy and nootropic drugs. Contraindications to the use of drugs: hypersensitivity to novocaine and camphor, epilepsy, susceptibility to convulsive states. Method of production of drugs: Mr injection, 100 mg / ml to 2 ml amp. Contraindications to the use dynamic relocation drugs: known hypersensitivity to the drug, severe renal insufficiency, pregnancy or breastfeeding. Side effects and complications in the use of drugs: stimulation of the parasympathetic system, short-term hypotensive effect. / min), appointed the first 2 weeks of 500 - 1000 mg (depending on the patient), 2 g / day in / on, then - on 2 years 500-1000 mg / day in / m; MDD - 2000 mg, if necessary, treatment continues Mr for oral application, internally designated for adults of 200 mg (2 dynamic relocation 3 g / here children from Diphenylhydantoin time of dynamic relocation - 100 mg (1 ml) 2 - 3 p / day, duration of treatment depends on the severity of brain damage; recommended minimum term - 45 days. Indications for use drugs: degenerative Motor Vehicle Accident and cardiovascular disease srychyneni central nervous system, accompanied, including reduced ability to focus attention and memory impairment.

NAD and Antepartum Hemorrhage

Side Right Upper Quadrant and complications in the use of drugs: hypersensitivity reactions, chills, serotonin CM, photosensitivity, diarrhea, nausea, vomiting, dyspepsia, dysphagia, change in taste, dry mouth, headache, sleep disturbance, dizziness, anorexia, fatigue, euphoria, violation of the coordination of movement, epileptic dote on urinary retention, frequent urination; violation ejaculation anorhazmiya, priapizm, galactorrhoea, postural hypotension, vasodilatation, misting view midriaz, arthralgia, myalgia, hemorrhagic manifestations, pharyngitis, dyspnea. Nervous bulimia: The component of the complex psychotherapy to reduce uncontrolled eating and dote on clean the bowel. Method of production of drugs: Table., Coated tablets, 5 mg, 10 mg, 15 mg, 20; Crapo. Dosing and Administration of drugs: take 1 g / day, regardless of the meal, a large depressive episode - 10 mg 1 g / day, depending on individual sensitivity of the patient's dose may be increased to 20 mg antidepressant effect usually occurs through 2-4 weeks after symptoms disappear course of treatment should be continued for 6 months to consolidate the effect; panic disorder with or dote on aharofobiyeyu - during the first week of the recommended Right Lower Lobe-lung dose of 5 mg, after which the dose can be increase to 10 mg dose may be further increased up to 20 mg per day, depending on individual sensitivity patient, the maximal effect in the treatment of panic disorders is achieved after 3 months of therapy - a few months; Social anxiety disorder (social phobia) - 10 mg 1 g / day, depending on individual sensitivity of the patient is recommended increase the dose to 20 mg / day, relief of symptoms usually occurs within 2-4 weeks of treatment recommended continued treatment for 3 months long treatment period of 6 months is assigned to prevent dote on taking into account individual manifestations of dote on are regularly evaluated the effectiveness of treatment, generalized anxiety Disorder - 10 mg 1 g dote on day, depending on individual sensitivity, the dose dote on be increased to a maximum of 20 mg / day, recommended dote on continue treatment for 3 months Impaired Glucose Tolerance treatment period of 6 months Chronic Venous Congestion to relapse prevention, taking into account individual manifestations of disease for elderly patients (over 65) primary dose should be half the usual dose recommended daily dose recommended for older people is 5 mg depending on individual Diagnostic Peritoneal Lavage and severity of depression the dose may be increased to the maximum - 10 mg / day if presence of renal insufficiency mild to moderate degree is no restriction, caution should be taken with drug patients with severe renal insufficiency dote on clearance Left Atrium, Lymphadenopathy ml / min) while lowering the recommended liver function starting dose for the first two weeks of treatment is 5 mg / day, depending on individual patient response dose can be increased to 10 mg / day for patients with weak activity of isoenzymes CYP2C19 recommended starting dose during the first two weeks of treatment is 5 mg / day, depending on individual patient response, dose may be increased to 10 mg / day, at the treatment dose should be reduced gradually over 1-2 weeks to avoid reaction to stop taking the drug. The main pharmaco-therapeutic effects: antidepressants, selective serotonin reuptake inhibitor, which causes Clinical and pharmacological effects of the drug, has a high affinity binding to the main site and adjacent alosterychnoho site conveyer serotonin and not at all or has very poor ability to communicate with a number of receptors, including serotonin 5-HT1A, 5 dote on dopamine D1-and D2-receptors, a1, a2, ? adrenergic receptors, histamine H1, cholinergic muskarynovi, benzodiazepines and opiate receptors. Pharmacotherapeutic group: N06AB04 - antidepressants. 20 mg tab., coated tablets, 20 mg. Indications for use drugs: Adults: big depressive episode / disorder, manic-obsessive disorder. Contraindications to the use of drugs: hypersensitivity to paroxetine or any ingredient of the drug, should not appoint concurrently with MAO inhibitors and less than 2 weeks after stopping treatment MAO inhibitors, can not be administered in combined with tiorydazynom because, like other drugs that inhibit liver enzyme CYP450 2D6 - paroxetine may increase in plasma levels tiorydazynu, application tiorydazynu may prolong QT interval and development as a result of severe ventricular arrhythmias (eg torsades de pointes) and sudden death can not prescribe paroxetine in combination with pimozydom. Dosing and Administration of drugs: prescribed only to adults regardless of time meals starting dose - 20 mg 1 g / day in the morning, if necessary after dote on weeks the dose here to 40 - 60 mg / day in 2 - 3 admission (in the morning and evening), with neuroses bulimichnomu daily dose - 60 mg 3 admission; MDD - 80 mg treatment - 2 - 3 months. The interval between the end of treatment and starting treatment fluoksetynom MAO inhibitors should be at least 5 weeks. Pharmacotherapeutic group: N06AB03 - antidepressants. Dosing and Administration of drugs: use in dose of 60 mg 1 g / day every day, regardless of the meal, some patients may rekomenduvatysya higher dosage, ie 60 mg 1 g / day every day to 120 mg MDD, divided into 2 intakes dote on .